Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea

Launched by CHONG KUN DANG PHARMACEUTICAL · Apr 21, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to manage medications for patients who have received a heart transplant. Specifically, the study will evaluate the effectiveness and safety of using a lower dose of certain medications called calcineurin inhibitors (CNI) combined with another medication called Everolimus. The goal is to see if this combination can help heart transplant patients in Korea while minimizing potential side effects.

To participate in the trial, individuals must be at least 19 years old and have stable heart function at least 28 days after their transplant. However, patients who have received another organ transplant, had a heart from a donor whose blood type did not match, or received a heart from an older donor (70 years or older) will not be eligible. While the trial is not yet recruiting participants, those who join can expect to be closely monitored to ensure the safety and effectiveness of the treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Over 19 years old
• • 2. Patients with stable heart transplant graft function at least 28\~100 days post transplant.
• • 3. Patients who are appropriate for combination therapy with Everolimus and Calcineurin inhibitor (CNI) at the investigator's discretion
• Exclusion Criteria:
• • 1. Recipients who have had a prior organ transplant, or who underwent a heart transplant with the simultaneous transplantation of another organ.
• • 2. Recipients of heart from ABO-incompatible donor
• • 3. Recipients of heart from the donor aged 70 or older